Abstract
Prehypertension, defined as blood pressure between 120–139/80–89 mmHg, is a major public health concern. The condition is very prevalent (30% of the adult population), is often associated with other cardiovascular risk factors and independently increases the risk of hypertension and subsequent cardiovascular events. The mechanism of elevated risk for cardiovascular events associated with prehypertension is presumed to be the same as that of hypertension. In the general population, prehypertension can be lowered by lifestyle modifications, but often not reliably. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) recommendation for prehypertension management with optimal weight control (largely through diet and exercise) remains the mainstay, except for individuals with diabetes, chronic kidney disease, and perhaps known coronary artery disease, because of the shot-term cost considerations and unproven long-term prognosis. The recently published Trial of Preventing Hypertension (TROPHY) is the first study of pharmacologic intervention among those with prehypertension. Results from this trial demonstrated that angiotensin receptor blockade (ARB) retards age-related blood pressure increases in prehypertensive patients. In this review, we discuss the options for pharmacologic intervention of prehypertension, with a focus on the TROPHY trial results.
Similar content being viewed by others
Article PDF
References
Chobanian AV, Bakris GL, Black HR, et al: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute. Hypertension 2003; 42: 1206–1252.
Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
Julius S, Jamerson K, Mejia A, et al: The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure Study. JAMA 1990; 264: 354–358.
Vasan RS, Larson MG, Leip EP, et al: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–1297.
Neaton JD, Kuller L, Stamler J, Wentworth DN : Impact of systolic and diastolic blood pressure on cardiovascular mortality. in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. New York, Raven Press, 1995, pp 127–144.
Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stamler J : Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998; 158: 2007–2014.
Greenlund KJ, Croft JB, Mensah GA : Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000. Arch Int Med 2004; 164: 2113–2118.
Chobanian AV : Prehypertension revisited. Hypertension 2006; 48: 812–814.
Vasan RS, Beiser A, Seshadri S, et al: Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002; 287: 1003–1010.
Mainous AG, Everett CJ, Liszka H, King DE, Egan BM : Prehypertension and mortality in a nationally representative cohort. Am J Cardiol 2004; 94: 1496–1500.
Okosun IS, Boltri JM, Anochie LK, Chandra KMD : Racial/ethnic differences in prehypertension in American adults: population and relative attributable risk of abdominal obesity. J Hum Hypertens 2004; 18: 849–855.
Tsai P-S, Ke T-L, Huang C-J, et al: Prevalence and determinants of prehypertension status in the Taiwanese general population. J Hypertens 2005; 223: 1355–1360.
Cordero A, Laclaustra M, Leon M, et al: Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. Am J Hypertens 2006; 19: 189–196.
Zhang Y, Lee ET, Devereux RB, et al: Prehypertension, diabetes, and cardiovascular disease risk in a populationbased sample: the Strong Heart Study. Hypertension 2006; 47: 410–414.
Lee JE, Kim Y-G, Choi Y-H, Huh W, Kim DJ, Oh HY : Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension 2006; 47: 962–967.
King DE, Egan BM, Mainous AG, Geesey ME : Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens 2004; 6: 562–568.
Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C : Association between prehypertension status and inflammatory markers related to atherosclerotic disease. The ATTICA Study. Am J Hypertens 2004; 17: 568–573.
Papadopoulos DP, Makris TK, Krespi PG, et al: Adiponectin and resistin plasma levels in healthy individuals with prehypertension. J Clin Hypertens 2005; 7: 729–733.
Toikka JO, Laine H, Ahotupa M, et al: Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension 2000; 36: 929–933.
Washio M, Tokunaga S, Yoshimasu K, et al: Role of prehypertension in the development of coronary atherosclerosis in Japan. J Epidemiol 2004; 14: 57–62.
Erdogan D, Caliskan M, Yildirim I, et al: Effects of normal blood pressure, prehypertension and hypertension on left ventricular diastolic function and aortic elastic properties. Blood Press 2007; 16: 114–121.
Liszka HA, Mainous AG, King DE, Everett CJ, Egan BM : Prehypertension and cardiovascular morbidity. Ann Fam Med 2005; 3: 294–299.
Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE : Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med 2006; 199: 133–141.
Qureshi AI, Suri FK, Kirmani JF, Divani AA, Mohammed Y : Is prehypertension a risk factor for cardiovascular diseases; Stroke 2005; 36: 1859–1863.
Fox KM, European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.
PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.
Patel A, MacMahon S, Chalmers J, et al: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–840.
Harada K, Karube Y, Saruhara H, Takeda K, Kuwajima I : Workplace hypertension is associated with obesity and family history of hypertension. Hypertens Res 2006; 29: 969–976.
Light KC, Turner JR, Hinderliter AL : Job strain and ambulatory work blood pressure in healthy young men and women. Hypertension 1992; 20: 214–218.
Fiedler N, Favata E, Goldstein BD, Gochfeld M : Utility of occupational blood pressure screening for the detection of potential hypertension. J Occup Med 1988; 30: 943–948.
Schnall PL, Schwartz JE, Landsbergis PA, Warren K, Pickering TG : Relation between job strain, alcoholic, and ambulatory blood pressure. Hypertension 1992; 19: 488–494.
James GD, Pickering TG, Yee LS, Harshfield GA, Riva S, Laragh JH : The reproducibility of average ambulatory, home, and clinic pressures. Hypertension 1988; 11: 545–549.
Sacks FM, Svetkey LP, Vollmer WM, et al, DASH–Sodium Collaborative Research Group: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3–10.
Appel LJ, Sacks FM, Carey VJ, et al, OmniHeart Collaborative Research Group: Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005; 294: 2455–2464.
Appel LJ, Champagne CM, Harsha DW, et al, Writing Group of the PREMIER Collaborative Research Group: Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003; 289: 2083–2209.
Elmer PJ, Obarzanek E, Vollmer WM, et al, PREMIER Collaborative Research Group: Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Int Med 2006; 144: 485–495.
Julius S, Nesbitt S, Egan B, et al, TROPHY Study Group: Trial of preventing hypertension: design and 2-year progress report. Hypertension 2004; 44: 146–151.
Nesbitt SD, Julius S, Leonard D, Egan BM, Grozinski M : Is low-risk hypertension fact or fiction? Cardiovascular risk profile in the TROPHY study. Am J Hypertens 2005; 18: 980–985.
Julius S, Nesbitt SD, Egan BM, et al: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–1697.
Julius S : Should the results of TROPHY affect the JNC 7 definition of prehypertension? Curr Hypertens Rep 2007; 9: 202–205.
Kjeldsen SE, Narkiewicz K, Hedner T : An American TROPHY in the prevention of hypertension. Blood Press 2006; 15: 132–134.
Suri MF, Qureshi AI : Prehypertension as a risk factor for cardiovascular diseases. J Cardiovasc Nurs 2006; 21: 478–484.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papadopoulos, D., Makris, T. & Papademetriou, V. Is It Time to Treat Prehypertension?. Hypertens Res 31, 1681–1686 (2008). https://doi.org/10.1291/hypres.31.1681
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.1681